Recent Headlines
Within Biotechnology
NWLS Transfers Marketing License Relating to Innovative Topical Drug Delivery to Atlan International
New Life Scientific, Inc. (OTCBB: NWLS), a company which specializes in the development of new biotechnology products and pharmaceuticals, announced today that it has transferred marketing rights to Atlan International(OTC: ATLI) of license agreement for two platform technologies (patent pending)... - February 27, 2007 - New Life Scientific, Inc.
Colorado Bioscience Association Showcases the State’s Most Promising Technologies
Colorado research institutions have begun reaping the rewards of legislation allocating state funds for bioscience research. HB 1360, sponsored by Representative Jim Reisberg (D-Greeley) and Senator Ron Tupa (D-Boulder), was signed into law by Governor Bill Owens last summer. $2 million in state funds was awarded to 27 bioscience proof of concept projects at six Colorado universities and research institutions. Initial reports are expected by the end of 2007. - February 23, 2007 - Colorado BioScience Association
Twenty-Four Colorado Companies Exhibited at the West Coast's Largest Design and Manufacturing Show, MD&M West
Twenty-four Colorado-based companies exhibited at the 23rd annual Medical Device & Manufacturing (MD&M) West show in Anaheim, CA, February 13-15. Colorado has a strong medical device manufacturing sector and was well represented at the MD&M trade show and conference. Several of Colorado’s regional economic development agencies were also in Anaheim assisting exhibiting companies and promoting the State of Colorado as a great place for doing business. - February 16, 2007 - Colorado BioScience Association
HiTIS - Life Science & Biotech Intelligence, A Global Life Sciences Industry Focused Competitive Intelligence Firm, Launched Skin Diseases Drug Development Weekly
HiTIS - life science & biotech intelligence, a global life sciences industry focused competitive intelligence firm, launched Skin Diseases Drug Development Weekly while the American Academy of Dermatology held its 65th annual meeting. - February 12, 2007 - HiTIS - Life Science & Biotech Intelligence
Dosing Convenience is Mandatory to Keep Pace in the Pipeline Race of GLP-1 Analogs for Type 2 Diabetes
The Business Intelligence firm La Merie S.L. reported today that major diabetes companies are trying to keep pace with Eli Lilly and Amylin Pharmaceutical in the field of GLP-1 analogs to treat type 2 diabetes. Lilly’s and Amylin’s first-in-class, but twice-daily product exenatide... - February 06, 2007 - La Merie Business Intelligence
Overview on 2006 Sales of Top 20 Biologics to Be Released on February 26
A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26. - February 05, 2007 - La Merie Business Intelligence
PharmaTrials Announces Expansion Plan into Asia
Pharma Trials International, Inc. a subsidiary of New Life Scientific, Inc. (OTCBB: NWLS), specializes in providing clinical trial services, market research, and services to enable pharmaceutical, biotech and medical device companies worldwide to conduct research and to obtain regulatory approval... - February 01, 2007 - New Life Scientific, Inc.
Baxa Announces 2007 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Baxa Corporation announces the training schedule for its professional Skills Training, Academics and Resources (STAR) Center for pharmacy and cleanroom skills training. The STAR Center, a premier facility designed for cleanroom and pharmacy practice demonstration, is located at the company’s world headquarters south of Denver, Colorado. Baxa Corporation built the STAR Center to provide professional education on pharmacy practice, cleanroom principles and compliance to regulatory requirements. - January 22, 2007 - Baxa Corporation
Feel The Pow(d)er - Precise and Reproducible Addition of Powdery Substances
LAMBDA Laboratory Instruments introduces a new digitally controlled, programmable powder dosing instrument. It allows precise, reproducible, automatic and continuous addition of powders, powdery and crystalline substances without a spoon. - January 20, 2007 - LAMBDA Laboratory Instruments
Baxa Releases New Safety-Focused Product Catalog
New catalog is magazine-catalog style and focuses on safety. Pharmacy safety enhancement has guided every Baxa innovation since their first product introduction more than 30 years ago. That product, the Exacta-Med® Oral Dispenser, has been the industry standard for safe administration of oral liquid medications ever since. - January 19, 2007 - Baxa Corporation
Baxa Corporation Signs Co-Marketing Agreement with VIASYS MedSystems for Specialty Enteral Feeding Products
Baxa Corporation announces its agreement with VIASYS MedSystems to co-market a dedicated enteral feeding system for neonates that reduces catheter misconnection errors. The first syringes designed only for enteral feeding, Baxa Exacta-Med Enteral Syringes are available individually packaged in 20, 35 and 60 mL sizes. - January 18, 2007 - Baxa Corporation
Xcelience Launches Drug Development Consulting Service
The launch of Xpert Consulting will provide supplemental services to assist clients. - January 17, 2007 - Xcelience, LLC
The Right Balance Drives the Field of PPAR Agonist R&D
A strongly growing market of now more than US$ 6 billion in 2006 for only two PPAR gamma agonists founds the basis for a heavily researched field of next generation mono, dual or triple PPAR agonists with fine-tuned subtype combinations. - January 12, 2007 - La Merie Business Intelligence
“Patient Safety and Peak Performance Through Pharmacy Training” from Baxa Corporation Focuses on Pharmaceutical Compounding Safety Concerns & Solutions
“Patient Safety and Peak Performance Through Pharmacy Training” from Baxa Corporation is now posted on PublicRelationsNewsroom.com for media and professional access. The article discusses the history of sterile compounding in pharmacy practice, current state, and the need for a purpose-built facility that provides practical, hands-on training in pharmacy preparation and regulatory compliance in order to achieve the level of patient safety and performance excellence required in today’s pharmacy. - December 28, 2006 - Baxa Corporation
ASCB Poster Presents Immunocapture Techniques for Improved MMP Assay
At the annual conference of the American Society for Cell Biology, AnaSpec presented a technical poster documenting improved technology for MMP detection assays. In a previous poster, AnaSpec documented the use of highly sensitive FRET-peptide substrates for MMP detection. The latest poster... - December 19, 2006 - AnaSpec, EGT Group
“Oral Medication Dispensers in Clinical Research,” a Technical Paper from Baxa Corporation, is Now Posted at PublicRelationsNewsroom.com
“Oral Medication Dispensers in Clinical Research,” a Technical Paper from Baxa Corporation is now posted for media and professional access on PublicRelationsNewsroom.com. Oral dispensers (syringes), long recognized as the safest and most accurate method to administer oral liquid medications, are especially valuable in clinical research where dosage accuracy has fundamental importance. - December 14, 2006 - Baxa Corporation
Fluorinated Building Blocks Produce Molecules with Enhanced Physiological Activities
The substitution of the fluorine in place of hydrogen in building blocks, such as amino acids, has produced molecules with enhanced physiological activities (1-2). Some of these are antibacterial, antihypertensive and antitumoral (3). One reason for the enhanced activity is that fluorine forms a... - December 12, 2006 - AnaSpec, EGT Group
Eric Kastango, MBA, RPh, is Now Profiled at the Expert Information for Journalists Website
Eric Kastango, president and CEO of Clinical IQ and frequent consultant to Baxa Corporation on hospital pharmacy safety issues is now profiled on the Expert Information For Journalists Web site – Expert411.com. Baxa Corp., a privately held company, is a leader in serving hospital pharmacy systems for handling, packaging and administering liquid medications from oral to multi-ingredient IV. Baxa is a registered medical device manufacturer with the FDA and has sales in more than 35 countries. - December 07, 2006 - Baxa Corporation
Baxa Corporation Introduces New Enteral Dispensers to Prevent Tubing Misconnections
Baxa Corporation announces new syringe-type dispensers designed for enteral feeding only to prevent wrong-route administration of non-IV fluids. The new Baxa Exacta-Med® Enteral Dispensers feature a unique dispenser tip that cannot connect to a luer needle or needleless IV system. - December 05, 2006 - Baxa Corporation
Baxa to Sponsor Exhibitor’s Theatre: The Perils and Pitfalls of Developing and Maintaining a Compliant Cleanroom
Colorado-based pharmacy products manufacturer, Baxa Corporation, is sponsoring a program at the annual American Society of Health-System Pharmacists’ Midyear Clinical Meeting in Anaheim. The speaker will discuss basic facility requirements for USP 797 compliance and the challenge of integrating primary engineering controls into facilities. - December 04, 2006 - Baxa Corporation
NeuroMedix Poised to Realize Next Stage of Business Plan through Strategic Alliance or Acquisition
After very successful pre-clinical trials for its lead product ‘Minozac,’ Neuromedix is planning further work on this promising Alzheimer’s treatment. - December 01, 2006 - Neuromedix Inc.
Functional Genetics, Inc. Announces Two Separate Awards from the United States Defense Threat Reduction Agency (DTRA) to Combat Viral Diseases
Functional Genetics, Inc. announced today that it has received two different awards from the United States Defense Threat Reduction Agency for the discovery and development of therapeutics for Ebola virus and other viral pathogens. "These awards from DTRA will greatly assist our mission of... - December 01, 2006 - Functional Genetics, Inc.
New Technology Makes Performance Enhancing Drugs and Altitude Training Obsolete
Those seeking natural performance enhancement look to new technology that produces many of the same performance enhancing effects as steroids, EPO blood doping and high altitude / hypoxia training systems without the effort, cost or risks. - November 30, 2006 - EarthPulse Tech, LLC
Weekly Monitor Drug and Diagnostic Development in Neurodegenerative Diseases
HiTIS - life science & biotech intelligence, a European life sciences industry focused competitive intelligence firm, recently launched Neurodegenerative Diseases Therapeutics & Diagnostics Competitive Intelligence Weekly - November 30, 2006 - HiTIS - Life Science & Biotech Intelligence
Gamma Medica-Ideas Announces Agreement to Acquire and Merge Operations with Advanced Molecular Imaging
Los Angeles and Oslo based Gamma Medica Ideas, Inc. (GM-I), a leader in providing next-generation medical imaging devices for the pre-clinical and clinical markets, announced today that it had reached agreement to acquire and merge operations with Sherbrooke, Canada based Advanced Molecular... - November 28, 2006 - Gamma Medica-Ideas
HiTIS - Life Science & Biotech Intelligence Expands Web Presence with www.txpreview.com
HiTIS - life science & biotech intelligence, a European life sciences industry- focused competitive intelligence firm, has released its corporate website. - November 23, 2006 - HiTIS - Life Science & Biotech Intelligence
Put an Eye on the Weekly Electronic Publication Covering Drug and Device-Based Available Treatments, Current Research and Upcoming Therapies Addressing Eye Disorders
HiTIS - life science & biotech intelligence, a life sciences industry focused competitive intelligence firm, has released the 26th weekly issue of its Eye Care industry competitive intelligence publication: Eye Therapies Competitive Intelligence Weekly (ETCI Weekly). - November 20, 2006 - HiTIS - Life Science & Biotech Intelligence
"USP 797 Training Requirements: A Case Study," Detailing Experiences at Swedish Medical Center/Seattle, Now Posted on PublicRelationsNewsroom.com
"USP 797 Training Requirements: A Case Study" published by Baxa Corporation is now posted for media and professional access on PublicRelationsNewsroom.com. This paper summarizes the process used by Swedish Medical Center in Seattle, WA to comply with the personnel training and evaluation in aseptic manipulation skills required by the United States Pharmacopeia (USP) Chapter 797. - November 16, 2006 - Baxa Corporation
Cornerstone BioPharma, Inc. Obtains Exclusive Licensing Rights for Spectracef
Triangle-based specialty pharmaceutical company to serve $1.3 billion per year oral cephalosporin market - November 09, 2006 - Cornerstone BioPharma
Baxa Releases New 2 mL Exacta-Med® Dispenser for Oral Medication Delivery
New Exacta-Med Dispenser size provides another dosing option for oral liquid medications. Exacta-Med Oral Dispensers were the first syringes developed specifically for safe delivery of oral liquids. Baxa is the market leader for oral dispensing devices. - October 31, 2006 - Baxa Corporation
Researchers Validate Important New in Vivo Imaging Research Method for Studying Drug Efficiency and Disease Progression
Study Results Show that Accurate in Vivo Quantitation of Drug Distribution and Therapeutic Effect is Possible and Important - October 26, 2006 - Gamma Medica-Ideas
Reputed Orthopaedic Surgeon to Join Business Intelligence Services Firm HiTIS Team as Scientific and Medical Advisor
Life science industry-focused competitive intelligence services practice adds outstanding orthopaedics expertise to founding team to develop new competitive intelligence periodical reports. - October 17, 2006 - HiTIS - Life Science & Biotech Intelligence
Gamma Medica-Ideas Awarded Grant to Develop SPECT/MRI Imaging Instrument
Gamma Medica-Ideas (GM-I) has been awarded a $100,000 grant to develop a SPECT/MRI small animal imaging system. The grant is part of an $850,000 fast-track grant award from the National Institutes of Health’s National Institute of Biomedical Imaging and Bioengineering. Dr. Douglas... - October 05, 2006 - Gamma Medica-Ideas
Sleep is Most Important Factor in Achieving Peak Athletic Performance
Sleep is one of the most underestimated factors in athletic performance. Sleep deprived athletes have a reduced response time of up to 75% and fatigue related deficits can mean the difference between a medal or a loss. - September 25, 2006 - EarthPulse Tech, LLC
Baxa Corporation Signs Co-Marketing Agreement with Unit Dose Solutions Inc.
Denver-based Baxa Corporation announces the signing of an exclusive co-marketing agreement with Unit Dose Solutions Inc. of Morrisville, NC. Under the agreement, Baxa will market and sell the oral unit dose repackaging services provided by Unit Dose Solutions. UDS serves hospital and alternate-care providers by offering an outsourcing alternative for unit dose packaging and labeling. - September 22, 2006 - Baxa Corporation
Delivery Improvements of the AMD-drug Lucentis on the Way
The anti-VEGF Fab Lucentis is the new standard of care to treat AMD because it can improve visual acuity. Competitor drugs directed against the same and innovative targets are applied with non-intravitreal forms of administration to avoid the unease of intra-vitreal injection. - September 20, 2006 - La Merie Business Intelligence
InViragen Announces Exclusive Patent License Agreement with the Centers for Disease Control
InViragen, LLC, a biotechnology company dedicated to developing vaccines for emerging infectious diseases worldwide, has entered into an Exclusive Patent License Agreement with the Centers for Disease Control and Prevention (CDC). The licensed technology is applicable to vaccines against multiple viral diseases, including dengue fever and West Nile disease. Dengue fever threatens 2.5 billion people worldwide as well as travelers to tropical countries. - September 14, 2006 - Colorado BioScience Association
Baxa Corporation’s UK Subsidiary, Baxa Ltd, Announces Direct Sales and Marketing Operations In Austria
Baxa Ltd, subsidiary of Denver-based Baxa Corporation, has moved to a direct sales and marketing model for the Austrian market. The company provides systems and devices for simplifying the handling, mixing and administration of fluid medications. Direct operations will provide Baxa Ltd with improved customer access for product development and continuous improvement, while continuing their excellent customer service. - September 12, 2006 - Baxa Corporation
Biologics Define New Standard of Therapy in Psoriasis
Anti-TNF agents set the new gold standard of psoriasis treatment which could be outperformed by smarter next generation biologics and small molecules in safety and convenience. - September 08, 2006 - La Merie Business Intelligence
Leading Colorado Biotechnology and Medical Device Companies Selected to Present at BIO Mid-America VentureForum
Five Colorado-based companies have been selected to present at the Biotechnology Industry Organization (BIO) Mid-America VentureForum to be held September 25-27th at the InterContinental Hotel in Cleveland, Ohio. These companies are among more then 50 companies selected by venture capitalists from the nation’s leading firms who serve on BIO’s advisory board. - September 07, 2006 - Colorado BioScience Association
New Life Scientific Moves into New Headquarters
New Life Scientific, Inc (NWLS) a developmental biotech company whose core focus is to develop and commercialize novel biotech/pharmaceutical products including vaccines and stem cell based treatment modalities and to expand through our own research, collaborations, acquisitions and in-licensing,... - September 01, 2006 - New Life Scientific, Inc.
Gamma-Medica-Ideas Introduces New Tri-Modality FLEX Triumph™ Pre-Clinical Imaging System
Gamma Medica-Ideas (GM-I) will unveil its new FLEX Triumph™ tri-modality pre-clinical imaging system at the Society of Molecular Imaging’s annual meeting in Hawaii this week. FLEX Triumph is GM-I’s fifth generation pre-clinical imaging system. It can be configured with PET,... - August 31, 2006 - Gamma Medica-Ideas
ApopLogic Pharmaceuticals Wins the Second Annual Faegre & Benson Venture Showcase Award, Presented at BioWest 2006
ApopLogic Pharmaceuticals has won the second annual Faegre & Benson Venture Showcase Award at the BioWest 2006 conference in Denver. The announcement is made by Chris Shapard, bioscience director at the Colorado Office of Economic Development and International Trade (OEDIT), who says the $10,000 Venture Showcase Award was again provided by the Faegre & Benson law firm and announced at the Colorado Bioscience Association (CBSA) Awards banquet held Thurs. evening at the Colo. Convention Center. - August 25, 2006 - Colorado BioScience Association
Baxa Opens Skills Training, Academics and Resources (STAR) Center for Pharmacy and Cleanroom Skills Training
Baxa Corporation is holding a ribbon-cutting ceremony today for a new, first-in-the-industry, strategic training center. The STAR Center offers pharmacy training for peak performance. First classes begin September 20th at the Englewood, Colo., location.. The STAR Center, the only dedicated facility of its kind in the world for hands-on cleanroom experience and training in environmental monitoring and aseptic technique, provides a unique opportunity for industry professionals to learn. - August 23, 2006 - Baxa Corporation
Colorado BioScience Association Announces Winners of Its 2006 Awards Program, Honoring the Best of Colorado's Bioscience Industry
The Colorado BioScience Association (CBSA) has released winners of its 2006 Awards Program. Official presentation of the awards occurs Thursday evening, August 24, 6:30 – 8:30 p.m., at the CBSA’s annual awards banquet. Held in conjunction with the 2006 BioWest conference at the Colorado Convention Center, registration information is available at the 2006 BioWest Conference website. - August 18, 2006 - Colorado BioScience Association
The Crowded Field of VEGF and VEGF-R Targeting Drugs
The versatility of the vascular endothelial growth factor (VEGF) signalling pathway as a validated target and its excellent tractability explain a crowded field of drugs of all classes. - August 17, 2006 - La Merie Business Intelligence
Blue Sky Biotech, Inc Appoints Scott Gridley, Ph.D., as Senior Research Scientist
Blue Sky Biotech, Inc. announced the June 1st appointment of Scott Gridley, Ph.D., as Senior Research Scientist. Dr. Gridley previously worked for five years in the metabolic diseases division of Sandoz Research Institute (now Novartis Institutes for BioMedical Research) where he was involved in... - August 15, 2006 - Blue Sky Biotech, Inc.
Baxa Corporation’s Claude Hooton Featured in Leadership Strategy Book, Inside the Minds: The Health Care Management Team
Claude Hooton, Executive Vice President of Sales and Marketing for Baxa Corporation was recognized for his leadership through his contribution to the recently released book, Inside the Minds: The Health Care Management Team. Hooton’s contribution joins those of CEOs, CTOs and other leaders to provide insight into the best leadership practice in the health care industry. - August 11, 2006 - Baxa Corporation
Baxa Corporation Releases Abacus™ v2 Order Entry and Calculation Software for TPN
The new version of Abacus, the specialized Baxa software for managing orders and calculations for total parenteral nutrition, is now available. The Windows-based system is the industry-leading program for automated compounding. Designed by health-system pharmacists, Abacus v2 ensures safety and reduces the opportunity for user error in the prescribing, calculating and mixing of multi-source compounds. - August 09, 2006 - Baxa Corporation
Baxa Corporation Selected as Second-Place Winner for Best Company to Work For in Colorado
In a ceremony held today in Westminster, Colorado – Englewood-based Baxa Corporation was selected in second place for best large company to work for in Colorado. Candidate choice followed finalist selection based on employee surveys by the Society for Human Resource Management. - August 03, 2006 - Baxa Corporation